Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cediranib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 11/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 5/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 4/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 4/20 | 1.00 |
| ▸ | TEK | Q02763 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | ERN1 | O75460 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cediranib SCHEMBL63147 | 1.00 | KDR (1.00) | KDRFLT4RETFLT1PDGFRB | |
| Cediranib SCHEMBL29368143 | 1.00 | KDR (1.00) | KDRFLT4RETFLT1PDGFRB | |
| Cediranib SCHEMBL29383181 | 1.00 | KDR (1.00) | KDRFLT4RETFLT1PDGFRB | |
| SCHEMBL1685423 | 0.99 | ABCB11 (1.00) | KDRFLT4RETFLT1PDGFRB | |
| SCHEMBL20077514 | 0.94 | KDR (0.89) | KDRFLT4RETFLT1PDGFRB | |
| Cediranib SCHEMBL4186434 | 0.94 | KDR (0.89) | KDRFLT4RETFLT1PDGFRB | |
| SCHEMBL3198096 | 0.94 | KDR (0.89) | KDRFLT4RETFLT1PDGFRB | |
| SCHEMBL13471998 | 0.94 | KDR (0.89) | KDRFLT4RETFLT1PDGFRB | |
| SCHEMBL1401668 | 0.94 | KDR (0.89) | KDRFLT4RETFLT1PDGFRB | |
| SCHEMBL1401641 | 0.93 | KDR (0.88) | KDRFLT4RETFLT1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6884 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4071174-B1 | METHODS COMPRISING FIXED INTERMITTENT DOSING OF CEDIRANIB | ASTRAZENECA AB (SE) | 2026-05-27 | — | — | EP | claimed |
| EP-4735045-A2 | OXAZAPHOSPHORINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | La Life Products, LLC (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4729519-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| EP-4719387-A2 | COMPLEMENT ANTIBODY-DRUG CONJUGATES | ADS Therapeutics LLC (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| US-12576085-B2 | Combination comprising an ATP analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer | SAWYER MICHAEL BRUCE (CA) | 2026-03-17 | — | — | US | claimed |
| US-12576077-B2 | Composition for preventing, alleviating or treating cancer | CKP THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-20260034056-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES OR DISORDERS | ALCON INC (CH) | 2026-02-05 | — | — | US | claimed |
| CN-114075159-A | Purification method and application of olapari | 吉林汇康制药有限公司 | 2022-02-22 | — | — | CN | claimed |
| WO-2022020720-A9 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TCR2 Therapeutics Inc. (US) | 2022-02-17 | — | — | WO | claimed |
| EP-3953390-A1 | HUMAN ANTIBODIES THAT BIND RET AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| US-11246864-B2 | Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization | ADS THERAPEUTICS LLC (US) | 2022-02-15 | — | — | US | claimed |
| WO-2022032113-A1 | PHARMACEUTICALS FOR TREATING OR PREVENTING NIDOVIRUSES AND PICORNAVIRUSES | THE UNIVERSITY OF CHICAGO (US) | 2022-02-10 | — | — | WO | claimed |
| CN-114010787-A | Compositions and methods for treating pterygium | 拨云生物医药科技(广州)有限公司 | 2022-02-08 | — | — | CN | claimed |
| WO-2022026510-A1 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB, A TAXANE, AND A VEGFR-2 ANTAGONIST | SEAGEN INC. (US) | 2022-02-03 | — | — | WO | claimed |
| CN-113993898-A | Human antibodies that bind RET and methods of use thereof | 瑞泽恩制药公司 | 2022-01-28 | — | — | CN | claimed |
| WO-2022020720-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TCR2 Therapeutics Inc. (US) | 2022-01-27 | — | — | WO | claimed |
| CN-113967261-A | Application of FOLR1 inhibitor and medicine mixture for treating liver cancer | 中国科学院大连化学物理研究所 | 2022-01-25 | — | — | CN | claimed |